Highlights Chiome Bioscience Inc.

Equities

4583

JP3205350006

Delayed Japan Exchange Other stock markets 10:30:00 2024-04-30 pm EDT			5-day change	1st Jan Change
123 ^JPY	-0.81%		-3.91%	-8.89%

Apr. 01	Chiome Bioscience Cancels License Agreements with ADC Therapeutics	MT
Feb. 13	Chiome Bioscience Inc. Announces Entrustment Agreement with Takeda Pharmaceutical Company Limited	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Chiome Bioscience Inc. Announces Entrustment Agreement with Takeda Pharmaceutical Company Limited	Feb. 13	CI
Chiome Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 13	CI
Chiome Bioscience Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 14	CI
Chiome Bioscience Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-09	CI
Chiome Bioscience Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Chiome Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-14	CI
Chiome Bioscience Inc. Provided Sales Guidance for 2023	23-02-14	CI
Henlius Biotech Terminates License Agreement for Chiome Bioscience's Tumor Drug	23-01-17	MT
Chiome Bioscience Inc. Announces Termination of the License Agreement for Anti-TROP-2 Antibody Development and Commercialization with Shanghai Henlius Biotech, Inc	23-01-17	CI
Chiome Bioscience Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-11-14	CI
Chiome Bioscience Signs Research and Option Agreement with Heidelberg Pharma	22-07-14	MT
Heidelberg Pharma Enters Research Collaboration Deal With Japan's Chiome Bioscience	22-07-13	MT
Chiome Bioscience Inc. Announces Conclusion of Target-Specific Research and Option Agreement with Heidelberg Pharma	22-07-13	CI
Chiome Bioscience, Rohto Pharmaceutical Sign Deal for Generation of Therapeutic Antibody	22-07-11	MT
Chiome Bioscience Inc. Announces Service Agreement with Option Contract with Rohto Pharmaceutical Co., Ltd	22-07-11	CI
Chiome Bioscience Inc. Announces First Patient in of Cancer Therapeutic Antibody CBA-1535 in A Phase 1 Clinical Trial	22-07-04	CI
Chiome Bioscience Inc. Announces Conclusion of Contract with Additional Institutes and First Dosing of CBA-1205 in the Second Part of Phase 1 Study	22-06-13	CI
Chiome Bioscience, Kidswell Bio to Collaborate on Development of Cancer Antibody	22-05-27	MT
Chiome Bioscience's Partner Begins Sale of Diagnostic Kit in Japan	22-04-22	MT
Chiome Bioscience Seeks to Conduct Phase I Study of Cancer Therapeutic Antibody	22-02-17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Chiome Bioscience Inc.

Equities

4583

JP3205350006

Highlights

Filters